Medicare AdvantagePrior AuthMedium impact
Saphnelo™ (anifrolumab-fnia) (Revised)
Humana·Rheumatology, Internal Medicine·Medicare Advantage
Effective date
May 27, 2026
We identified it
Jun 25, 2026
Summary
Humana Medicare Advantage revised its Saphnelo (anifrolumab-fnia) prior authorization policy effective May 27, 2026. The policy maintains existing coverage criteria for moderate-to-severe SLE patients on standard combination therapy, requires autoantibody confirmation (ANA, anti-dsDNA, anti-Sm), and mandates specialist prescribing. All Saphnelo formulations (IV solution, Pen auto-injector, and syringe) require prior authorization with plan year duration approvals.
Action Required
By May 27, 2026: Billing and clinical teams must ensure all Saphnelo (anifrolumab-fnia) claims for Medicare Advantage members include prior authorization. Verify prior auth requirements in billing system for all Saphnelo formulations (IV solution, Pen subcutaneous auto-injector, subcutaneous syringe). Before submitting claims: (1) Confirm member diagnosis of moderate-to-severe SLE with documented autoantibodies (ANA, anti-dsDNA, or anti-Sm); (2) Verify member is on concurrent standard SLE therapy (prednisone, hydroxychloroquine, azathioprine); (3) Confirm prescriber is a rheumatologist or SLE specialist; (4) Exclude members with severe active lupus nephritis or CNS lupus; (5) For renewal requests, obtain clinical documentation of response/low disease activity. Route all Saphnelo requests through prior authorization process before dispensing. Claims submitted without prior authorization will be denied. Update encounter templates and provider communication materials to emphasize specialist-only prescribing requirement.